Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorLeipzig Heart Science gGmbH
About this trial
Prospective, randomized, controlled, multicenter, open-label trial to study whether multivessel percutaneous coronary intervention (PCI) is superior over culprit-lesion only PCI in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease.
Eligibility criteria
Qualifiers
NSTEMI as suggested by high-sensitivity troponin algorithms
Multivessel coronary artery disease
Identifiable culprit lesion
Informed consent
Disqualifiers
Age <18 years
Cardiogenic shock
Sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)
Contraindication for coronary revascularization
Trial design
Treatments tested in this trial
- Culprit-lesion revascularization
- Non-culprit-lesion revascularization
Treatment groups
3,390 Participants
are divided into 2 treatment groupsLocations
58Austria
LKH Univ. Klinikum Graz, Clinical Department of Cardiology8036, Graz Austria
Medizinische Universität Innsbruck, Universitätsklinik für Innere Medizin III6020, Innsbruck Austria
Klinik Ottakring, 3. medizinische Abteilung1160, Vienna Austria
Germany
Zentralklinik Bad Berka, Klinik für Kardiologie99437, Bad Berka Germany
Sponsors and collaborators
Leipzig Heart Science gGmbH
Lead sponsor
Heart Center Leipzig at University of Leipzig
Collaborator
German Federal Ministry of Education and Research
Collaborator
IHF GmbH - Institut für Herzinfarktforschung
Collaborator
Stiftung IHF - Institut für Herzinfarktforschung
Collaborator
Source ClinicalTrials.gov